Arena Pharmaceuticals (ARNA), which soared over 10% in Monday morning trading, has set a new 52-week high of $6.75. Over the past month, Arena signed a licensing deal for its potential weight-loss drug, lorcaserin, with Japan's Eisai; released study results for the drug; and got a boost from a decision by a Food and Drug Administration panel on rival's Vivus (VVUS) drug. Arena's shares have more than doubled during that time.

The Eisai licensing deal is potentially worth about $1.3 billion. Meanwhile, the study results Arena released showed lorcaserin helped nearly half the patients lose 5% of their weight and improved their chances of keeping it off. Arena's drug did that while exhibiting a safer safety profile than either of its competitors' treatments: Vivus's Qnexa and Orexigen's (OREX) Contrave.

Pharmaceutical company Vivus (VVUS) has lost more than half of its value in pre-market trading Friday. Unfortunately for VVUS, the Food and Drug Administration (FDA) rejected the company's Qnexa weight-loss drug late Thursday -- citing a lack of long-term safety data.

The news triggered a glut of downgrades and target price cuts, including downgrades from Brean Murray, Needham, JP Morgan, and Jefferies.

The drop for VVUS is understandable when considering that Qnexa is the company's main drug. There is a slight (ever-so-slight) glimmer of hope for VVUS, as the FDA is not obliged to follow the recommendations of its panels. Of course, the agency usually does follow the recommendations of its panels.

MOST NOTEWORTHY: First Solar, JA Solar, Alcatel-Lucent, Nokia and Ericsson were today's noteworthy initiations:

• First Solar (NASDAQ: FSLR) and JA Solar Holdings (NASDAQ: JASO) were initiated with Buy ratings and targets of $160 and $61 at Collins Stewart. Collins Stewart sees room for margin expansion and is positive on First Solar after channel checks; the firm expects JA Solar to expand capacity given its long-term supply agreements with four wafer suppliers.
  
• Merrill Lynch started shares of Alcatel-Lucent (NYSE: ALU) with a Sell rating, citing a lack of revenue growth prospects.
  
• The firm also started shares of Nokia Corporation (NYSE: NOK) with a Buy rating, as they believe the company's share gains and margin expansion will continue.
  
• Merrill also resumed coverage of Ericsson (NASDAQ: ERIC) with a Neutral rating, expecting high single digit earnings and share growth, but not enough for a Buy rating.

OTHER INITIATIONS:

• Goldman initiated the trucking and railroad sectors with Neutral ratings.
  
• Wachovia initiated Isis Pharmaceuticals (NASDAQ: ISIS), BioMarin and Molecular Insight (NASDAQ: MIPI) with Outperform ratings and Bioenvision (NASDAQ: BIVN), Dendreon Corporation (NASDAQ: DNDN), Arena Pharmaceuticals (NASDAQ: ARNA) and Neurocrine Biosciences (NASDAQ: NBIX) with Market Perform ratings.

MAJOR PAPERS:

• According to people familiar with the matter, Home Depot Inc (NYSE: HD) was close to accepting about $1.2B less for the sale of its wholesale distribution business to three private-equity firms, but there was uncertainty about whether the deal would close by last night's deadline, reported the Wall Street Journal (subscription required).
• Ford Motor Company (NYSE: F) CEO Alan Mulally urged the Federal Reserve to stimulate the economy and focus on economic growth, reported the Financial Times (subscription required).

OTHER PAPERS:

• British energy company BP plc (NYSE: BP) is warning that a fierce environmental campaign may force it to scrap a $3.8B expansion at one of America's biggest oil refineries, reported the U.K. Times.
• From BusinessWeek's "Inside Wall Street" column:
  
• Spirits company Diageo plc (NYSE: DEO) may be the perfect tonic for jittery markets, and could appreciate 20% to 25% annually for several years, said Randy Haase of Baron Fifth Avenue Growth Fund.
  
• As household budgets get squeezed, consumers are likely to spend more at discount retailers - and TJX Companies Inc (NYSE: TJX), owner of T.J . Maxx, is one of the best bets.
• In September, Arena Pharmaceuticals Inc (NASDAQ: ARNA) will announce 6-month safety review for its lead drug, lorcaserin, an obesity drug, which is in a large phase III test.

Cramer on tonight's MAD MONEY discussed his new favorite biotech play.

Cramer gave a backgrounder: he said on Jan 11 his Zymogenetics, Inc. (NASDAQ:ZGEN) pick is now up 15% and he still likes it. He also discussed Myogen, Inc. (NASDAQ:MYOG) because it is being acquired by Gilead Sciences, Inc. (NASDAQ:GILD) and he picked MYOG to be bought. He wanted to look for another Myogen.

Cramer has a new favorite name in biotech development is Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). He said Arena has a weight loss drug in its pipeline, and it should be a huge revenue generator. He said it isn't just because of obesity, but people are (after all) fond of spending money to look good, and will take it for this purpose, too. He said this drug in Phase III does not have the side effects of the offerings from other obesity drug companies.

After Cramer discussed this it popped 7% after-hours, resulting in market capitalization of $603 million as of the $12.75 close. He did note ahead of his call not to trade it right after he discussed it in after-hours "because you'll get robbed."

Cramer was also positive on Amgen, Inc. (NASDAQ:AMGN) and Genentech, Inc. (NYSE:DNA).

Jon Ogg is a partner in 24/7 Wall St.; he does not own securities in any of the companies he covers.